Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

doi:10.1001/jamaoncol.2014.257

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

JAMA oncology - 1 May 2015

Karachaliou Niki, Mayo-de las Casas Clara, Queralt Cristina, de Aguirre Itziar, Melloni Boris, Cardenal Felipe, Garcia-Gomez Ramon, Massuti Bartomeu, Sánchez José Miguel, Porta Ruth, Ponce-Aix Santiago, Moran Teresa, Carcereny Enric, Felip Enriqueta, Bover Isabel, Insa Amelia, Reguart Noemí, Isla Dolores, Vergnenegre Alain, de Marinis Filippo, Gervais Radj, Corre Romain, Paz-Ares Luis, Morales-Espinosa Daniela, Viteri Santiago, Drozdowskyj Ana, Jordana-Ariza Núria, Ramirez-Serrano Jose Luis, Molina-Vila Miguel Angel, Rosell Rafael

Abstract excerpt

IMPORTANCE: The EURTAC trial demonstrated the greater efficacy of erlotinib compared with chemotherapy for the first-line treatment of European patients with advanced non-small-cell lung cancer (NSCLC) harboring oncogenic epidermal growth factor receptor (EGFR) mutations (exon 19 deletion or L858R mutation in exon 21) in tumor tissue. OBJECTIVE: To assess the feasibility of using circulating free DNA (cfDNA) from...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chi-Square Distribution

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to Erlotinib Hydrochloride

Share to Feasibility Studies

Share to Kaplan-Meier Estimate

Share to Multivariate Analysis

Share to Proportional Hazards Models

Share to Real-Time Polymerase Chain Reaction

Source

Open in PubMed

Identifiers

PMID: 26181014
DOI: 10.1001/jamaoncol.2014.257

Genes

EGFR

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.PMID 26181014Read ↗

EGFR mutation analysis on circulating free DNA in NSCLC: a single-center experience.Semantic proximity Read ↗

Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy.Semantic proximity Read ↗

Analysis of the effect of baseline detection and early clearance of ct-DNA, on survival outcomes among patients with advanced EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.Semantic proximity Read ↗

A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.Semantic proximity Read ↗

Assessment of high-sensitive methods for the detection of EGFR mutations in circulating free tumor DNA from NSCLC patients.Semantic proximity Read ↗

Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancerSemantic proximity Read ↗

Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02).Semantic proximity Read ↗

Detection of EGFR mutations in plasma DNA from lung cancer patients by mass spectrometry genotyping is predictive of tumor EGFR status and response to EGFR inhibitors.Semantic proximity Read ↗

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.